Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 27, Number 5—May 2021
Dispatch

Longevity of Middle East Respiratory Syndrome Coronavirus Antibody Responses in Humans, Saudi Arabia

Abeer N. Alshukairi1Comments to Author , Jincun Zhao1, Maha A. Al-Mozaini, Yanqun Wang, Ashraf Dada, Salim A. Baharoon, Sara Alfaraj, Waleed A. Ahmed, Mushira A. Enani, Fatehi E. Elzein, Nazik Eltayeb, Laila Layqah, Aiman El-Saed, Husam A. Bahaudden, Abdul Haseeb, Sherif A. El-Kafrawy, Ahmed M. Hassan, Najlaa A. Siddiq, Ibtihaj Alsharif, Isamel Qushmaq, Esam I. Azhar2, Stanley Perlman2, and Ziad A. Memish2
Author affiliations: King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia (A.N. Alshukairi, A. Dada, N.A. Siddiq, I. Qushmaq); First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China (J. Zhao, Y. Wang); King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia (M.A. Al-Moziani, I. Alsharif); King Abdulaziz Medical City, Riyadh (S.A. Baharoon, A. El-Saed); Prince Mohammed Bin Abdulaziz Hospital, Riyadh (S. Alfaraj); Security Forces Hospital, Makkah, Saudi Arabia (W.A. Ahmed); King Fahad Medical City, Riyadh (M.A. Enani); Prince Sultan Military Medical City, Riyadh (F.E. Elzein, N. Eltayeb); King Abdullah International Medical Research Center, Riyadh (L. Layqah); King Saud bin Abdulaziz University for Health Sciences, Jeddah (H.A. Bahaudden); Umm Al Qura University, Makkah, Saudi Arabia (A. Haseeb); King Abdulaziz University, Jeddah (S.A. El-Kafrawy, A.M. Hassan); King Fahd Medical Research Center, Jeddah (E.F. Azhar); University of Iowa, Iowa City, Iowa, USA (S. Perlman); King Saud Medical City, Riyadh (Z.A. Memish); Al-Faisal University, Riyadh (Z.A. Memish)

Main Article

Table

Clinical and serologic findings for 48 patients 2–6 y after infection with Middle East respiratory syndrome coronavirus, Saudi Arabia*

Patient ID Age, y/sex Time, y between serologic analysis and infection Diagnosis Disease or condition Illness grade ELISA result ELISA titer NT titer NT result
46 34/F 6 AS Healthy Mild – 0.0 <20 –
47 41/M 6 AS Healthy Mild – 0.02 40 +
48 41/F 6 PN Healthy Moderate – 0.76 320 +
45 42/M 6 PN Healthy Moderate – 0.75 80 +
43 56/M 6 SPN Healthy Severe – 3.0 80 +
44 38/F 6 SPN Pregnant, thyroid disease Severe + 2.4 80 +
1 52/F 5 URTI HPT, thyroid disease Mild – 0.1 <20 –
2 43/F 5 URTI Healthy Mild – 0.3 42 +
15 35/M 5 PN DM, hyperlipidemia Moderate B 0.8 30 +
33 39/F 4 URTI Healthy Mild – 0.7 28 –
7 49/M 4 URTI DM, HPT, BA, IHD, ESRD Mild + 1.5 104 +
34 42/F 4 URTI HPT Mild + 1.9 144 +
40 28/F 4 URTI Healthy Mild NP NP 40 +
41 32/F 4 AS Healthy Mild NP NP 41 +
31 33/M 4 URTI Healthy Mild – 0.5 34 +
32 45/F 4 URTI Healthy Mild B 0.9 44 +
3 45/M 4 PN Smoker Moderate + 1.1 48 +
5 61/M 4 PN DM, HPT, IHD Moderate + 2.9 160 +
25 28/M 4 PN Healthy Moderate + 2.5 315 +
42 47/M 4 PN Healthy Moderate NP NP 351 +
45 42/M 4 PN Healthy Moderate NP NP 162 +
29 58/M 3 URTI Healthy Mild – 0.1 45 +
23 28/M 3 URTI Healthy Mild – 0.1 42 +
8 47/M 3 URTI HPT, hyperlipidemia Mild + 2.5 320 +
18 55/M 3 URTI DM Mild + 3.4 648 +
20 34/M 3 URTI Healthy Mild – 0.6 81 +
26 39/M 3 URTI Healthy Mild – 0.6 75 +
35 63/M 3 URTI DM Mild + 2.5 501 +
37 61/M 3 URTI DM, HPT Mild + 1.2 81 +
14 32/F 3 AS Healthy Mild – 0.1 45 +
39 34/M 3 URTI Healthy Mild + 1.2 31 +
9 36/F 3 URTI Healthy Mild – 0.2 32 +
6 74M 3 URTI DM, lipid Mild – 0.1 <20 –
10 46/F 3 AS Healthy Mild – 0.1 20 –
11 47/F 3 AS Grave’s disease Mild – 0.1 20 –
12 33/F 3 AS Healthy Mild – 0.3 20 –
17 54/F 3 URTI HPT, thyroid disease Mild + 4.3 <20 –
27 29/M 3 URTI Healthy Mild – 0.1 <20 –
30 41/F 3 URTI Healthy Mild – 0.2 <20 –
4 41/M 3 PN Stroke Moderate + 3.4 446 +
19 50/M 3 PN Healthy Moderate + 3.7 315 +
24 54/M 3 PN DM, HPT, myocarditis Moderate + 2.4 398 +
22 57/M 3 PN Asthma Moderate + 1.9 41 +
16 62F 3 SPN Asthma, hyperlipidemia Severe + 2.6 416 +
21 34/F 3 SPN Healthy Severe + 2.4 375 +
28 38/M 3 SPN Healthy Severe + 1.8 117 +
13 59/M 3 SPN Healthy Severe – 0.1 20 –
36 64/M 2 URTI Healthy Mild + 2.5 160 +
38 34/M 2 URTI Healthy Mild – 0.3 27 +

*AS, asymptomatic; B, borderline; BA; bronchial asthma; DM, diabetes mellitus; ESRD, end-stage renal disease; HPT, hypertension; IHD, ischemic heart disease; NP, not performed; NT, neutralization test; PN, pneumonia; SPN, severe pneumonia (patients were in intensive care unit and required intubation and ventilation); URTI, upper respiratory tract infection; –, negative; +, positive.

Main Article

1These authors contributed equally to this article.

2These senior authors contributed equally to this article.

Page created: February 09, 2021
Page updated: April 21, 2021
Page reviewed: April 21, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external